External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?
Paula Jiménez-FonsecaAlberto Carmona-BayonasEva Martínez de CastroAna CustodioCarles Pericay PijaumeRaquel HernandezGema AguadoNatalia Castro UnanuaJuana María CanoFlora LópezMarcelo GarridoAna Fernández MontesLaura VisaManuel Sánchez CánovasMaría Luisa LimónNieves Martínez LagoPaola PimentelAlicia HurtadoAitor AzkárateFederico LongoMarc DiezAranzazu Arias-MartinezTamara SauriAlfonso Martín CarniceroMonserrat MangasMarta Martín RichardMónica GranjaAvinash RamchandaniCarolina Hernández PérezPaula CerdáAitziber Gil-NegreteMariona CalvoRosario Vidal TocinoJavier GallegoPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2020)
Our study confirms the effect of DPF is highly dependent on several clinical-pathological variables, with discreet and gradually declining benefit over platinum doublets in later years, at the expense of increased toxicity. These results may help to underpin the idea that external validity of AGC trials should be revised regularly.